A pilot study of GE-137 fluorescence imaging to improve the accuracy of surgical excision in patients with breast cancer or oral cancer
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2016
At a glance
- Drugs EMI-137 (Primary)
- Indications Early breast cancer; Orofacial cancer; Squamous cell cancer
- Focus Diagnostic use
- 11 Dec 2015 Accrual to date is 2% according to United Kingdom Clinical Research Network record.
- 03 Dec 2015 Status changed from not yet recruiting to recruiting, according to United Kingdom Clinical Research Network record.
- 15 Aug 2015 New trial record